Subutex (Buprenorphine) - Prices & Where to Buy

What Is Subutex?

Subutex is the brand name for buprenorphine without naloxone. Buprenorphine is a partial mu-opioid agonist used for the treatment of opioid use disorder (OUD) and, in other formulations, for pain management.

The key difference between Subutex and Suboxone is that Subutex contains only buprenorphine, while Suboxone combines buprenorphine with naloxone (an opioid antagonist included as a misuse deterrent). Subutex is particularly important in pregnancy, where buprenorphine without naloxone is generally preferred.

Subutex is designated as a Schedule III controlled substance.

How Subutex Works

Buprenorphine is a partial mu-opioid agonist. It binds to mu-opioid receptors in the brain and spinal cord but only partially activates them. This produces:

• Sufficient opioid effect to reduce withdrawal symptoms and cravings
• A ceiling effect — beyond a certain dose, no additional opioid effect occurs, reducing respiratory depression risk
• High receptor binding affinity — it tightly occupies mu receptors, preventing other opioids from binding

Buprenorphine has a long half-life of approximately 24 to 42 hours, allowing for once-daily or even less frequent dosing. In the sublingual formulation, it is absorbed through the oral mucosa with a bioavailability of approximately 30—50%.

FDA Schedule & Classification

FDA-Approved Uses

Opioid Use Disorder

Buprenorphine is FDA-approved for the induction and maintenance treatment of opioid dependence. It reduces withdrawal symptoms, decreases cravings, and blocks the effects of other opioids.

• Induction: Starting buprenorphine during opioid withdrawal
• Maintenance: Ongoing treatment to sustain recovery
• Pregnancy: Buprenorphine without naloxone is generally preferred for OUD during pregnancy

Pain Management

Buprenorphine is also used for pain management in various formulations:

• Butrans (transdermal patch): FDA-approved for moderate to severe chronic pain
• Belbuca (buccal film): FDA-approved for moderate to severe chronic pain
• Buprenorphine injection: Used in hospital settings for acute pain

Dosage Forms & Strengths

Sublingual Tablets (Opioid Use Disorder)

Other Buprenorphine Formulations

For opioid use disorder, the typical induction dose is started when the patient is in moderate withdrawal. The target maintenance dose is typically 8 to 16 mg per day, with a maximum of 24 mg per day.

Side Effects

Common Side Effects

• Headache
• Nausea and vomiting
• Constipation
• Sweating
• Insomnia
• Mouth numbness or pain (from sublingual administration)
• Dizziness
• Fatigue
• Back pain

Serious Side Effects

Contact your healthcare provider or seek emergency medical attention if you experience:

• Respiratory depression — especially with concurrent CNS depressant use
• Severe allergic reaction (anaphylaxis)
• Adrenal insufficiency
• Hepatotoxicity — jaundice, dark urine
• QT prolongation (rare)
• Neonatal withdrawal — if used during pregnancy

Drug Interactions

Major Interactions (Avoid or Use Extreme Caution)

• Benzodiazepines — profound sedation, respiratory depression, coma, and death
• Alcohol — additive CNS depression
• Other opioids — risk of respiratory depression and precipitated withdrawal
• MAO inhibitors — potentially dangerous interaction
• CYP3A4 inhibitors — may increase buprenorphine levels

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (rifampin, carbamazepine) — may decrease buprenorphine effectiveness
• Serotonergic drugs — theoretical risk of serotonin syndrome
• Antiretroviral drugs — some may interact with buprenorphine

Precautions & Warnings

• Pregnancy: Buprenorphine without naloxone (Subutex) is generally preferred during pregnancy for opioid use disorder treatment. The combination product (Suboxone) has less safety data in pregnancy. Neonates may require monitoring for withdrawal.
• Breastfeeding: Generally considered compatible with breastfeeding. Buprenorphine is excreted in small amounts.
• Liver disease: Use with caution in hepatic impairment. Monitor liver function.
• Precipitated Withdrawal: Must be in moderate withdrawal before starting to avoid precipitated withdrawal.
• Misuse potential: While lower risk than full agonists, Subutex can still be misused (e.g., injection, intranasal).
• Adrenal insufficiency: Monitor for symptoms of adrenal insufficiency with long-term use.
• Driving and machinery: May cause drowsiness, especially during induction.
• Emergency situations: Inform all healthcare providers that you are taking buprenorphine.

When to Contact a Clinician

• You are still experiencing cravings or withdrawal symptoms
• You notice new or unexpected side effects
• You are having difficulty functioning at work or home
• You are experiencing mood changes, depression, or thoughts of self-harm
• You are pregnant or planning to become pregnant
• You are thinking about stopping treatment — talk to your provider first
• You have been started on a new medication by another provider

Seek emergency care immediately if you experience difficulty breathing, severe allergic reaction, loss of consciousness, or symptoms of overdose.